BR112021016996A8 - Polipeptídeo com atividade antibacteriana, composição para prevenir ou tratar sepsis compreendendo a mesma e composição antibacteriana - Google Patents
Polipeptídeo com atividade antibacteriana, composição para prevenir ou tratar sepsis compreendendo a mesma e composição antibacterianaInfo
- Publication number
- BR112021016996A8 BR112021016996A8 BR112021016996A BR112021016996A BR112021016996A8 BR 112021016996 A8 BR112021016996 A8 BR 112021016996A8 BR 112021016996 A BR112021016996 A BR 112021016996A BR 112021016996 A BR112021016996 A BR 112021016996A BR 112021016996 A8 BR112021016996 A8 BR 112021016996A8
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- antibacterial
- prevent
- present
- antibacterial activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190023534 | 2019-02-28 | ||
KR1020200023629A KR102368983B1 (ko) | 2019-02-28 | 2020-02-26 | 항균활성을 갖는 폴리펩타이드, 이를 포함하는 패혈증 예방 또는 치료용 조성물, 및 항균용 조성물 |
PCT/KR2020/002826 WO2020175936A1 (ko) | 2019-02-28 | 2020-02-27 | 항균활성을 갖는 폴리펩타이드, 이를 포함하는 패혈증 예방 또는 치료용 조성물, 및 항균용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112021016996A2 BR112021016996A2 (US06244707-20010612-C00011.png) | 2021-11-30 |
BR112021016996A8 true BR112021016996A8 (pt) | 2022-11-22 |
Family
ID=72239598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021016996A BR112021016996A8 (pt) | 2019-02-28 | 2020-02-27 | Polipeptídeo com atividade antibacteriana, composição para prevenir ou tratar sepsis compreendendo a mesma e composição antibacteriana |
Country Status (5)
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115960171B (zh) * | 2022-10-12 | 2023-08-29 | 东北农业大学 | 高稳定性Trp-pocket跨链交互型β-发卡抗菌肽及制备方法和应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006060484A2 (en) * | 2004-12-01 | 2006-06-08 | Gene Therapy Systems, Inc. | Tuberculosis nucleic acids, polypeptides and immunogenic compositions |
AU2008316225B2 (en) * | 2007-10-26 | 2014-06-19 | Avivagen Inc. | Compositions and methods for enhancing immune response |
EP2344178B1 (en) * | 2008-10-05 | 2014-12-03 | Universita Degli Studi di Siena | Peptide sequences, their branched form and use thereof for antimicrobial applications |
HUE054437T2 (hu) * | 2011-05-20 | 2021-09-28 | H Lundbeck As | Anti-CGRP készítmények és alkalmazásuk |
WO2012177658A2 (en) * | 2011-06-19 | 2012-12-27 | New York Univeristy | Methods of treating and preventing staphylococcus aureus infections and associated conditions |
JP6338899B2 (ja) * | 2014-03-18 | 2018-06-06 | 国立研究開発法人産業技術総合研究所 | 両生類ネッタイツメガエル皮膚由来機能性ペプチド |
JP2018529689A (ja) * | 2015-09-17 | 2018-10-11 | ソウル大学校産学協力団Seoul National University R&Db Foundation | グラム陰性菌に対する抗菌活性を示す切断または折り畳まれたヘリックスペプチドまたはペプチド類似体およびその用途 |
KR101792239B1 (ko) * | 2016-11-01 | 2017-10-31 | 경북대학교 산학협력단 | 7,10-에폭시옥타데카-7,9-다이에노산 및 항생제를 유효성분으로 포함하는 항균 조성물 |
JP2020519731A (ja) | 2017-06-16 | 2020-07-02 | ボレアリス エージー | 光起電用途用ポリマー組成物 |
US11400136B2 (en) * | 2017-06-19 | 2022-08-02 | President And Fellows Of Harvard College | Methods and compositions for treating a microbial infection |
KR102011676B1 (ko) | 2017-08-29 | 2019-08-19 | (주) 한성스틸 | 벽난로 |
CN115298197A (zh) * | 2020-03-20 | 2022-11-04 | Hlb科学株式会社 | 用于去除脂多糖的组合物和试剂盒 |
KR20220027685A (ko) * | 2020-08-27 | 2022-03-08 | 단디바이오사이언스 주식회사 | 알츠하이머 치매 예방 또는 치료용 펩타이드 조성물 |
-
2020
- 2020-02-27 CA CA3168643A patent/CA3168643A1/en active Pending
- 2020-02-27 US US17/434,538 patent/US20220144892A1/en active Pending
- 2020-02-27 WO PCT/KR2020/002826 patent/WO2020175936A1/ko unknown
- 2020-02-27 JP JP2021549548A patent/JP7219512B2/ja active Active
- 2020-02-27 BR BR112021016996A patent/BR112021016996A8/pt unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022521543A (ja) | 2022-04-08 |
CA3168643A1 (en) | 2020-09-03 |
US20220144892A1 (en) | 2022-05-12 |
WO2020175936A1 (ko) | 2020-09-03 |
BR112021016996A2 (US06244707-20010612-C00011.png) | 2021-11-30 |
JP7219512B2 (ja) | 2023-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2017000186A (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
CL2019001079A1 (es) | Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina. | |
CR20160269A (es) | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento del cancer y enfermedades comunes | |
SV2018005614A (es) | Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias | |
CL2019002255A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas. | |
ECSP12012017A (es) | DERIVADOS DE SULFONAMIDA COMO AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CÁNCER Y ENFERMEDADES INMUNES | |
DOP2015000240A (es) | 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante | |
CR20120631A (es) | Agentes inductores de apoptosis para el tratamiento del càncer y de enfermedades inmunes y autoinmunes | |
BR112017010882B8 (pt) | Compostos de n-((het)-arilmetil)-heteroaril-carboxamidas como inibidores de calicreína plasmática e seus usos | |
UY33047A (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
BR112015022483A2 (pt) | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante | |
BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
BR112018014175A2 (pt) | composição antibacteriana e método para tratar infecções estafilocócicas com a composição antibacteriana | |
BR112017010602A2 (pt) | análogos de ureia ligados em ponte substituídos como moduladores de sirtuína | |
CL2019001746A1 (es) | Amidas aromáticas de ácido carboxílico | |
CO6592047A2 (es) | Formulación tópica oftálmica de péptidos | |
MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
BR112021016996A8 (pt) | Polipeptídeo com atividade antibacteriana, composição para prevenir ou tratar sepsis compreendendo a mesma e composição antibacteriana | |
BR112021018918A2 (pt) | Compostos e composições como moduladores de sinalização de tlr | |
MX2020009566A (es) | Compuestos como moduladores de la se?alizacion de tlr2. | |
WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES | |
BR112021011293A2 (pt) | Composição farmacêutica para prevenção ou tratamento de câncer compreendendo lactobacillus sakei wikim30 como ingrediente ativo | |
AR110913A1 (es) | Compuesto aminoglucósido y su uso para prevenir o tratar enfermedades infecciosas | |
BR112022012136A2 (pt) | Compostos macrocíclicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: HLB SCIENCE INC. (KR) |
|
B25G | Requested change of headquarter approved |
Owner name: HLB SCIENCE INC. (KR) |